Pain medicine

The OPIAID Zone Tool (Version 0.5) as a Composite Outcome for Postoperative Pain Management Quality

Acta Anaesthesiol ScandPublished prospective observational cohort pilot study

Authors' conclusion

The OPIAID Zone Tool (version 0.5) combines pain and ORADE scores into a single metric while simultaneously visualising their distribution across the population. The Zone score was associated with patient-centred outcomes and outperformed pain and ORADEs assessed separately, though a risk of overfitting cannot be ruled out. Further refinement and prospective validation are planned to optimise the tool and confirm its clinical utility.

Study context

Population
Adult patients undergoing orthopaedic and abdominal surgery under general anaesthesia with postoperative care in the post-anaesthesia care unit at Bispebjerg Hospital, Denmarkadult patients included
Participants
145 patients
Exposure
OPIAID Zone Tool score (version 0.5) against patient-perceived health (EQ-VAS), quality of recovery (QoR-PACU) and time to discharge readiness in PACU, compared with pain and opioid-related adverse drug events (ORADEs) assessed separately
Outcome
OPIAID Zone Tool score (version 0.5): distribution across OPIAID Zones

Main finding

As reported in the abstract

Zone 0
13.8%
Zone 1
6.9%
Zone 2
22.1%
Zone 3
18.6%
Zone 4
20.0%
Zone 5
18.6%

Observational data: associations, not effects.

Further findings

Association of OPIAID Zone Tool score with EQ-VAS, QoR-PACU and PACU discharge readiness (secondary analyses)

EQ-VAS R2
0.39
QoR-PACU R2
0.35
PACU discharge readiness R2
0.50
Stronger overall associations than pain and ORADEs assessed separately
  • Significantly associated
  • Evaluated using R2, AIC and BIC

Original publication

The OPIAID Zone Tool (Version 0.5) as a Composite Outcome for Postoperative Pain Management Quality. Acta Anaesthesiol Scand. Published 5 October 2026. doi:10.1111/aas.70349

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.